NEWS & EVENTS

The MSA encompasses development of ISM-001 from cell line development through to finished clinical trial product supply; work will be performed in the USA and the EU.

Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s AAV vector-based therapeutic candidates for use in clinical trials.

Experts and speakers from Catalent and JLABS will be joined by speakers from Johnson & Johnson and Cardiff Advisory LLC.

OneBio Suite offers customers an integrated service to accelerate programs from development to manufacturing, including fill/finish and packaging, and support for clinical supply and commercial launch.

Under the terms of the agreement, Catalent is authorized to collaborate with its customers to evaluate BRL’s formulation technology to reduce viscosity and deliver high-concentration biologic products.

Catalent today announced the expansion of its UpTempo℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.

The state-of-the-art facility contains development and manufacturing space across multiple cleanrooms for the dedicated production of CGMP-grade pDNA for clinical and commercial-phase supply

The new Case Management Service addresses challenges associated with delivering advanced therapies to patients by providing supply chain oversight from program start to finish.

Mr. Zayas will be responsible for Catalent’s North American biologics operations. He will serve on the Executive Leadership Team, reporting directly to President & CEO, Alessandro Maselli.